Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$129K Buy
84,000
+15,700
+23% +$50.4K ﹤0.01% 5680
2014
Q2
$232K Sell
68,300
-10,400
-13% -$35.9K ﹤0.01% 5000
2014
Q1
$279K Buy
78,700
+28,800
+58% +$196K ﹤0.01% 4831
2013
Q4
$306K Buy
49,900
+700
+1% +$3.86K ﹤0.01% 4833
2013
Q3
$286K Buy
49,200
+6,000
+14% +$31.1K ﹤0.01% 4756
2013
Q2
$196K Buy
+43,200
New +$205K ﹤0.01% 5116

Other funds holding EXEL

UBS's EXEL Position: Q3 2014 in Review

UBS increased its Exelixis (EXEL) stake by 1.6% in Q3 2014, buying an estimated $3.43K and bringing the position to 69,772 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #5916.

UBS first reported a position in EXEL in Q2 2013 and has held it in 6 quarters since. The position peaked at $242K in Q2 2013. 125 funds tracked by Wall St. Rank hold EXEL as of Q3 2014.

  • UBS held 69,772 shares of Exelixis worth $107K as of Q3 2014.
  • UBS bought 1,070 Exelixis shares in Q3 2014, an estimated $3.43K.
  • Exelixis made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5916 holding.
  • UBS first reported a position in Exelixis in Q2 2013 and has held it in 6 quarters since.
  • UBS's Exelixis position peaked at $242K in Q2 2013.
  • 125 funds tracked by Wall St. Rank held Exelixis as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.